Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.


Journal

The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246

Informations de publication

Date de publication:
03 2020
Historique:
received: 15 04 2019
revised: 12 11 2019
accepted: 21 11 2019
pubmed: 19 2 2020
medline: 7 7 2020
entrez: 19 2 2020
Statut: ppublish

Résumé

Treatment outcomes among survivors of cancer diagnosed during adolescence and early young adulthood have not been characterised independently of survivors of cancers diagnosed during childhood. We aimed to describe chronic health conditions and all-cause and cause-specific mortality among survivors of early-adolescent and young adult cancer. The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study with longitudinal follow-up of 5-year survivors diagnosed with cancer before the age of 21 years at 27 academic institutions in the USA and Canada between 1970 and 1999. We evaluated outcomes among survivors of early-adolescent and young adult cancer (aged 15-20 years at diagnosis) and survivors diagnosed at age younger than 15 years (matched on primary cancer diagnosis, including leukaemia, lymphoma, CNS tumours, neuroblastoma, Wilms tumour, soft-tissue sarcomas, and bone cancer) by comparing both groups to siblings of the same age. Mortality was ascertained with the National Death Index. Chronic health conditions were classified with the Common Terminology Criteria for Adverse Events. Standardised mortality ratios (SMRs) were estimated with age-specific, sex-specific, and calendar year-specific US rates. Cox proportional hazard models estimated hazard ratios (HRs) for chronic health conditions and 95% CIs. Among 5804 early-adolescent and young adult survivors (median age 42 years, IQR 34-50) the SMR compared to the general population for all-cause mortality was 5·9 (95% CI 5·5-6·2) and among 5804 childhood cancer survivors (median age 34 years; 27-42), it was 6·2 (5·8-6·6). Early-adolescent and young adult survivors had lower SMRs for death from health-related causes (ie, conditions that exclude recurrence or progression of the primary cancer and external causes, but include the late effects of cancer therapy) than did childhood cancer survivors (SMR 4·8 [95% CI 4·4-5·1] vs 6·8 [6·2-7·4]), which was primarily evident more than 20 years after cancer diagnosis. Early-adolescent and young adult cancer survivors and childhood cancer survivors were both at greater risk of developing severe and disabling, life-threatening, or fatal (grade 3-5) health conditions than siblings of the same age (HR 4·2 [95% CI 3·7-4·8] for early adolescent and young adult cancer survivors and 5·6 [4·9-6·3] for childhood cancer survivors), and at increased risk of developing grade 3-5 cardiac (4·3 [3·5-5·4] and 5·6 [4·5-7·1]), endocrine (3·9 [2·9-5·1] and 6·4 [5·1-8·0]), and musculoskeletal conditions (6·5 [3·9-11·1] and 8·0 [4·6-14·0]) when compared with siblings of the same age, although all these risks were lower for early-adolescent and young adult survivors than for childhood cancer survivors. Early-adolescent and young adult cancer survivors had higher risks of mortality and severe and life threatening chronic health conditions than the general population. However, early-adolescent and young adult cancer survivors had lower non-recurrent, health-related SMRs and relative risks of developing grade 3-5 chronic health conditions than childhood cancer survivors, by comparison with siblings of the same age, which were most notable more than 20 years after their original cancer. These results highlight the need for long-term screening of both childhood and early-adolescent and young adult cancer survivors. National Cancer Institute and American Lebanese-Syrian Associated Charities.

Sections du résumé

BACKGROUND
Treatment outcomes among survivors of cancer diagnosed during adolescence and early young adulthood have not been characterised independently of survivors of cancers diagnosed during childhood. We aimed to describe chronic health conditions and all-cause and cause-specific mortality among survivors of early-adolescent and young adult cancer.
METHODS
The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study with longitudinal follow-up of 5-year survivors diagnosed with cancer before the age of 21 years at 27 academic institutions in the USA and Canada between 1970 and 1999. We evaluated outcomes among survivors of early-adolescent and young adult cancer (aged 15-20 years at diagnosis) and survivors diagnosed at age younger than 15 years (matched on primary cancer diagnosis, including leukaemia, lymphoma, CNS tumours, neuroblastoma, Wilms tumour, soft-tissue sarcomas, and bone cancer) by comparing both groups to siblings of the same age. Mortality was ascertained with the National Death Index. Chronic health conditions were classified with the Common Terminology Criteria for Adverse Events. Standardised mortality ratios (SMRs) were estimated with age-specific, sex-specific, and calendar year-specific US rates. Cox proportional hazard models estimated hazard ratios (HRs) for chronic health conditions and 95% CIs.
FINDINGS
Among 5804 early-adolescent and young adult survivors (median age 42 years, IQR 34-50) the SMR compared to the general population for all-cause mortality was 5·9 (95% CI 5·5-6·2) and among 5804 childhood cancer survivors (median age 34 years; 27-42), it was 6·2 (5·8-6·6). Early-adolescent and young adult survivors had lower SMRs for death from health-related causes (ie, conditions that exclude recurrence or progression of the primary cancer and external causes, but include the late effects of cancer therapy) than did childhood cancer survivors (SMR 4·8 [95% CI 4·4-5·1] vs 6·8 [6·2-7·4]), which was primarily evident more than 20 years after cancer diagnosis. Early-adolescent and young adult cancer survivors and childhood cancer survivors were both at greater risk of developing severe and disabling, life-threatening, or fatal (grade 3-5) health conditions than siblings of the same age (HR 4·2 [95% CI 3·7-4·8] for early adolescent and young adult cancer survivors and 5·6 [4·9-6·3] for childhood cancer survivors), and at increased risk of developing grade 3-5 cardiac (4·3 [3·5-5·4] and 5·6 [4·5-7·1]), endocrine (3·9 [2·9-5·1] and 6·4 [5·1-8·0]), and musculoskeletal conditions (6·5 [3·9-11·1] and 8·0 [4·6-14·0]) when compared with siblings of the same age, although all these risks were lower for early-adolescent and young adult survivors than for childhood cancer survivors.
INTERPRETATION
Early-adolescent and young adult cancer survivors had higher risks of mortality and severe and life threatening chronic health conditions than the general population. However, early-adolescent and young adult cancer survivors had lower non-recurrent, health-related SMRs and relative risks of developing grade 3-5 chronic health conditions than childhood cancer survivors, by comparison with siblings of the same age, which were most notable more than 20 years after their original cancer. These results highlight the need for long-term screening of both childhood and early-adolescent and young adult cancer survivors.
FUNDING
National Cancer Institute and American Lebanese-Syrian Associated Charities.

Identifiants

pubmed: 32066543
pii: S1470-2045(19)30800-9
doi: 10.1016/S1470-2045(19)30800-9
pmc: PMC7392388
mid: NIHMS1564846
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-435

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA055727
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Cancer. 2018 Jan 1;124(1):136-144
pubmed: 28902390
Ann Intern Med. 2014 Jan 7;160(1):11-7
pubmed: 24573662
Radiat Res. 2006 Jul;166(1 Pt 2):141-57
pubmed: 16808603
CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55
pubmed: 17626120
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
J Clin Oncol. 2008 Jun 20;26(18):3038-45
pubmed: 18565890
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
J Clin Oncol. 2003 Apr 1;21(7):1359-65
pubmed: 12663727
JAMA Oncol. 2016 Feb;2(2):193-200
pubmed: 26584448
Glob J Health Sci. 2014 Oct 29;7(2):210-27
pubmed: 25716407
J Clin Endocrinol Metab. 2006 May;91(5):1723-8
pubmed: 16492690
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625
Biometrics. 2011 Mar;67(1):39-49
pubmed: 20377575
J Clin Oncol. 2014 Apr 20;32(12):1218-27
pubmed: 24638000
J Clin Oncol. 2015 Nov 10;33(32):3774-80
pubmed: 26304888
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320
pubmed: 28209594
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
J Clin Oncol. 2008 Sep 20;26(27):4401-9
pubmed: 18802152
Arch Intern Med. 2009 Aug 10;169(15):1381-8
pubmed: 19667301
J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32
pubmed: 10999813
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Curr Pediatr Rev. 2014;10(4):249-62
pubmed: 25403639
BMJ. 2016 Sep 01;354:i4351
pubmed: 27586237
Blood. 2008 Sep 1;112(5):1646-54
pubmed: 18502832
J Adolesc Young Adult Oncol. 2011 Mar;1(1):37-42
pubmed: 26812567

Auteurs

Eugene Suh (E)

Loyola University Chicago Health Sciences, Maywood, IL, USA.

Kayla L Stratton (KL)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Wendy M Leisenring (WM)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Paul C Nathan (PC)

The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Jennifer S Ford (JS)

Hunter College and The Graduate Center, City University of New York, New York, NY, USA.

David R Freyer (DR)

Children's Hospital Los Angeles, Los Angeles, CA, USA.

Jennifer L McNeer (JL)

Department of Pediatrics, University of Chicago, Chicago, IL, USA.

Wendy Stock (W)

Department of Medicine, University of Chicago, Chicago, IL, USA.

Marilyn Stovall (M)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kevin R Krull (KR)

St Jude Children's Research Hospital, Memphis, TN, USA.

Charles A Sklar (CA)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Joseph P Neglia (JP)

University of Minnesota, Minneapolis, MN, USA.

Gregory T Armstrong (GT)

St Jude Children's Research Hospital, Memphis, TN, USA.

Kevin C Oeffinger (KC)

Duke University School of Medicine, Durham, NC, USA.

Leslie L Robison (LL)

St Jude Children's Research Hospital, Memphis, TN, USA.

Tara O Henderson (TO)

Department of Pediatrics, University of Chicago, Chicago, IL, USA. Electronic address: thenderson@peds.bsd.uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH